Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Fineline Cube Aug 13, 2026
Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Fineline Cube Aug 13, 2026
Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026

Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ:...

Company Drug

Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients

Fineline Cube Aug 5, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s New...

Company Drug

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Fineline Cube Aug 5, 2026

Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application...

Company Drug

Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age

Fineline Cube Aug 5, 2026

Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has approved an extension of the...

Company

Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring

Fineline Cube Aug 5, 2026

Novo Nordisk (NYSE: NVO) today released its financial results for the second quarter of 2026,...

Company Drug

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

Fineline Cube Aug 5, 2026

Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name:...

Company

Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year

Fineline Cube Aug 5, 2026

Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026,...

Company

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

Fineline Cube Aug 5, 2026

AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance...

Company

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Fineline Cube Aug 5, 2026

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) released its first-half 2026 (H1’2026) financial results....

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026

Alphamab Oncology (HKG: 9966) announced that it has entered into a licensing agreement with Pathos...

Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026

In May 2026, Hunan Zonsen PepLib Biotech Inc. successfully completed a Series C financing round...

Company Drug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 5, 2026

CARsgen Therapeutics (HKG: 2171) announced that CT0596 has received clinical approval from the National Medical...

Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the combination regimen of orelabrutinib and...

Company Drug

Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC

Fineline Cube Aug 5, 2026

Adlai Nortye (NASDAQ: ANL) announced that the company’s independently developed antibody-drug conjugate (ADC) AN4035, which...

Company Drug

Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma

Fineline Cube Aug 4, 2026

Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced that the US Food and Drug Administration (FDA)...

Drug

FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States

Fineline Cube Aug 4, 2026

On July 29, 2026, the U.S. FDA granted a biologics license to Ezplaz Freeze Dried...

Company Drug

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

Fineline Cube Aug 4, 2026

Novartis (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto...

Company

HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline

Fineline Cube Aug 4, 2026

HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced its financial results for the six months...

Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026

Siemens Healthineers AG (ETR: SHL) and Cleveland Clinic announced the signing of a 10-year strategic...

Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026

Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) announced that it has signed a Strategic Cooperation Framework...

Posts pagination

1 … 4 5 6 … 707

Recent updates

  • Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea
  • CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership
  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.